Invion Ltd. · ASX:IVX
Invion — Shareholder Meeting (November 2025)
15 slides from Invion's shareholder meeting presentation, Nov 26, 2025
Slide 1: Annual General Meeting November 2025
For personal use only ANNUAL GENERAL MEETING November 2025 Next Generation Photodynamic Therapy (PDT) for Cancers and Infectious Diseases ASX: IVX
Slide 2: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p
Slide 3: Invion at Clinical Inflexion Point
PLATFORM TECHNOLOGY & PARTNERSHIPS INVION AT CLINICAL INFLEXION POINT For personal use only Progressing Clinical Programs Invion is well advanced in its clinical program across multiple cancer types with encouraging early results Photosoft is only activated by Platform Technology specific Significan
Slide 4: Year of Achievements: Continued Clinical Milestones & Partnerships
YEAR OF ACHIEVEMENTS CONTINUED CLINICAL MILESTONES & PARTNERSHIPS For personal use only Further Results Ph I/II Skin Achievements in 2024-25 Cancer Clinical Trial ✓ Collaboration with Protect Animal Health on companion animal cancers Initiation Ph I/II Anogenital ✓ Secured Orphan Drug Designation Cl
Slide 5: Collaboration with Protect Animal Health
COLLABORATION WITH PROTECT ANIMAL HEALTH LUCRATIVE COMPANION ANIMAL MARKET OPPORTUNITY New Market Potential For personal use only • First agreement in the companion animal cancer care market • Reinforces Photosoft as a platform technology with multiple market opportunities Founded in 2019 by biotech
Slide 6: Anogenital Cancer Trial Update: Orphan Drug Designation
ANOGENITAL CANCER TRIAL UPDATE ORPHAN DRUG DESIGNATION For personal use only Moving Towards Human Trials Orphan Drug Designation ▪ INV043 shows pre-clinical efficacy, ▪ U.S. FDA grants Orphan Drug Designation achieving ~80% tumour control in (ODD) to INV043 (Invion’s lead cancer mice when used in co
Slide 7: Combination with Immune Checkpoint Inhibitors (ICI)
COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICI) IMPROVING IMMUNOTHERAPY OUTCOMES, PARTNERSHIP POTENTIAL • Immune checkpoint inhibitors (ICI), a type of immunotherapy, is standard of care in treatment of several cancers • Despite widespread use of ICIs, the patient response rate can be as low as
Slide 8: Phase I/II Non-Melanoma Skin Cancer Trial: Safety Review Committee Findings
PHASE I/II NON-MELANOMA SKIN CANCER TRIAL SAFETY REVIEW COMMITTEE FINDINGS – INITIAL PATIENT GROUP Change in size of NMSC lesions Findings from Safety Review Committee (SRC) For personal use only treated and untreated lesions* (initial patient group of 6) ▪ No adverse events identified related to th
Slide 9: Evaluation of NMSC Therapies: Potential to Displace Standard of Care
EVALUATION OF NMSC THERAPIES1 POTENTIAL TO DISPLACE STANDARD OF CARE Non-Melanoma Skin Cancer (NMSC) Phase I/II Clinical Trial (Adaptive Trial Structure): Addressing the unmet need for one of the world’s most common cancers2 For personal use only GOOD INV043 (Topical) Metvix#/ALA PDT Treatment #by G
Slide 10: INV043 Fluoresces Cancers Under Violet Light
INV043 FLUORESCES CANCERS UNDER VIOLET LIGHT DIAGNOSTIC POTENTIAL Potential for INV043 to assist surgeons to more accurately remove cancers For personal use only Animal studies at Hudson Institute Patient 101-002 from Ph I/II NMSC Trial: Day 1 of the treatment • Primary pancreatic (Human PANC1) canc
Slide 11: Theragnostic Potential
THERAGNOSTIC POTENTIAL MULTIPLE CANCERS, PRECISION CANCER TARGETING, PROTECTIVE IMMUNITY SELECTIVE TARGETING PROTECTIVE IMMUNITY For personal use only Control Treated https://inviongroup.com/videos-reports/ • INV043 selectively retained in malignant but not healthy • Triple Negative Breast Cancer (T
Slide 12: Target Indications and Timeframes
TARGET INDICATIONS AND TIMEFRAMES MULTIPLE CLINICAL TRIALS AND INDICATIONS DISEASE AREA (CALENDAR YEAR) 1H2024 2H2024 1H2025 2H2025 >CY26 For personal use only CANCER1 Prostate Cancer (Funded by RMWC) Completed Follow up and monitoring Non-Melanoma Skin Cancers (Topical)2 Adaptive study design Anoge
Slide 13: Creating Impact for Treating Cancers Globally
CREATING IMPACT FOR TREATING CANCERS GLOBALLY NEED FOR MORE AFFORDABLE NEW TREATMENTS Commercial Rationale for Photosoft For personal use only Cost of new FDA drugs in 2023 jumped 35% YoY at median price of US$300K1, Works across multiple cancers without need making affordability even to personalise
Slide 14: Experienced Team
EXPERIENCED TEAM THE RIGHT EXPERTISE FOR SUCCESS PROF THIAN CHEW PROF ROBERT RAMSAY EXECUTIVE CHAIRMAN & CEO SCIENTIFIC ADVISOR For personal use only • Co-Founder, Chronic Airway Therapeutics • 30+ years research in cancer biology &translational medicine • Advisory Board, Stanford Medicine CARE • Se
Slide 15: For more information
For personal use only For more information, go to www.inviongroup.com Investor and Media enquiries: Thian Chew (Chairman & CEO) Brendon Lau (Investor & Media Relations) T: +61 3 9692 7222 M: +61 409 341 613 E: investor@inviongroup.com E: brendon.lau@inviongroup.com